Trial Profile

A Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selpercatinib (Primary) ; Cabozantinib; Vandetanib
Indications Medullary thyroid cancer; Thyroid cancer
Focus Registrational; Therapeutic Use
Acronyms LIBRETTO-531
Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd; Loxo Oncology

04 Feb 2025 The protocol has been amended change in time frame.
04 Feb 2025 Planned End Date changed from 28 Feb 2026 to 1 Feb 2026.
23 May 2024 According to an Eli Lilly and Company media release, data from this trial will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 - June 4 in Chicago.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com